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This phase I trial was designed to determine the safety and maximum tolerated dose (MTD) of tipifarnib in combination with
gemcitabine and cisplatin in patients with advanced solid tumours. Furthermore, the pharmacokinetics of each of these agents was
evaluated. Patients were treated with tipifarnib b.i.d. on days 1–7 of each 21-day cycle. In addition, gemcitabine was given as a 30-min
i.v. infusion on days 1 and 8 and cisplatin as a 3-h i.v. infusion on day 1. An interpatient dose-escalation scheme was used.
Pharmacokinetics was determined in plasma and white blood cells. In total, 31 patients were included at five dose levels. Dose-limiting
toxicities (DLTs) consisted of thrombocytopenia grade 4, neutropenia grade 4, febrile neutropenia grade 4, electrolyte imbalance
grade 3, fatigue grade 3 and decreased hearing grade 2. The MTD was tipifarnib 200mg b.i.d., gemcitabine 1000mgm
 2 and cisplatin
75mgm
 2. Eight patients had a confirmed partial response and 12 patients stable disease. No clinically relevant pharmacokinetic
interactions were observed. Tipifarnib can be administered safely at 200mg b.i.d. in combination with gemcitabine 1000mgm
 2 and
cisplatin 75mgm
 2. This combination showed evidence of antitumour activity and warrants further evaluation in a phase II setting.
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Tipifarnib (Zarnestra
s, R115777; Johnson & Johnson Pharmaceu-
tical Research and Development, Titusville, NJ) is a farnesyltrans-
ferase inhibitor (FTI) that can be administered orally. It exerts its
antitumour activity by preventing post-translational farnesylation
required for activation of selected proteins. Farnesyltransferase
inhibitors were initially designed to inhibit the post-translational
modification necessary for Ras activation (Kato et al, 1992), but
their mechanism of action seemed to be more complex involving
also other multifunctional proteins (Prendergast et al, 1994; Sepp-
Lorenzino et al, 1995; Maltese, 1998; Du and Prendergast, 1999).
Accumulating data have identified three polypeptides whose
inhibition may be the basis for the cytotoxic actions of FTIs.
These are polypeptides associated with the phosphoinositide 3-OH
kinase/AKT pathway (Jiang et al, 2000); G protein Rho B, which
regulates cytoskeletal organisation (Lebowitz and Prendergast,
1998); and the centromeric polypeptides CENP-E and CENP-F,
which interact with microtubules and are necessary for the
completion of mitosis (Ashar et al, 2000). Tipifarnib has shown
good anticancer activity in preclinical in vitro and in vivo studies
(End et al, 2001), and has subsequently been evaluated in single
agent phase I trials in patients with non-small-cell lung cancer
(NSCLC), cervix, colorectal, pancreatic cancer and leukaemia
(Zujewski et al, 2000; Karp et al, 2001; Crul et al, 2002). The most
common regimen for this agent in solid tumours is 300mg b.i.d.
for 21 consecutive days with 1 week off. Myelosuppression,
manifested typically as neutropenia, was the most common
toxicity. Other toxicities included fatigue, nausea, vomiting and
diarrhoea, which were usually mild in severity. In a continuous
schedule, sensory neuropathy was dose limiting. Several phase II
trials have demonstrated activity in patients with breast cancer,
malignant glioma and acute myelogenous leukaemia (AML)
(Cloughesy et al, 2002; Johnston et al, 2003; Gotlib, 2005).
Tipifarnib has also been investigated in two phase III trials in
patients with pancreatic cancer and colorectal cancer (Rao et al,
2004; Van Custem et al, 2004), but no improved efficacy could be
demonstrated. Currently, the combination of tipifarnib with
several classes of antineoplastic drugs is investigated. Preclinically,
the combination of tipifarnib with gemcitabine exhibited synergy
(Janssen Research Foundation, 2003), whereas the combination
with cisplatin was additive (Skrzat et al, 1999). Good activity of
combined gemcitabine and cisplatin has been demonstrated in a
number of malignancies, including NSCLC (Abratt et al, 1997;
Crino et al, 1997), head and neck cancer (H/N) (Hitt et al, 1998),
urothelial (Kaufman et al, 2000; van der Maase et al, 2000) and
cervical cancer (Burnett et al, 2000). On the basis of the preclinical
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sdata and the different mechanisms of antitumour activity of
gemcitabine, cisplatin and tipifarnib, a phase I trial was performed
of this combination. Since the compounds have some, but
potentially important, overlap in toxicity profiles (myelosuppres-
sion), a relatively short administration of tipifarnib of 7 days
was chosen. The primary objectives were: (i) to determine the
maximum-tolerated (MTD) dose, (ii) to characterise the dose-
limiting toxicities (DLTs) and (iii) to investigate the pharmacoki-
netics of each agent, in particular a possible influence of tipifarnib
on the pharmacokinetics of gemcitabine and cisplatin.
PATIENTS AND METHODS
Eligibility
Patients were eligible if they had a histologically or cytologically
confirmed advanced solid tumour for which no curative therapy
exists. Other eligibility criteria included a WHO performance
status of 0–2 and age X18 years. Previous radiotherapy or
anticancer chemotherapy had to be discontinued for X4 weeks
before entry into the study, or 6 weeks in case of nitrosourea or
mitomycin C. All patients had to have acceptable bone marrow
function, defined by neutrophil counts (ANC) X1500ml
 1,
platelets X100000ml
 1 and Hgb X5.6mmoll
 1; and adequate
hepatic and renal function defined as creatinine clearance
X50mlmin
 1, total bilirubin p1.5 upper limit of normal and
ASAT and ALAT p2.5 times the normal upper limit (or p5 times
the normal upper limit in case of hepatic metastases). The study
protocol was approved by the Medical Ethics Committee of the
hospital and all patients had to give written informed consent.
Treatment plan and study design
Tipifarnib was supplied by Johnson & Johnson Pharmaceutical
Research and Development as 100mg tablets. Gemcitabine and
cisplatin were supplied by the hospital pharmacy and were used
according to local regulatory requirements. Tipifarnib was
administered orally twice daily, with intervals of 12h. Tipifarnib
was given on days 1–7 of each 21-day cycle. Gemcitabine was
given as a 30-min i.v. infusion on days 1 and 8 and cisplatin was
given as a 3-h i.v. infusion on day 1, beginning 30min after
completion of the gemcitabine administration. To minimise
nephrotoxicity, a pre-and posthydration schedule was implemen-
ted on day 1. Pre- and posthydration consisted of 2000ml NaCl
0.45%/glucose 2.5% over 14h before treatment and 3000ml NaCl
0.45%/glucose 2.5% over 18h after cisplatin infusion. To
determine the influence of tipifarnib on the pharmacokinetics of
gemcitabine and cisplatin, administration of this agent was
omitted on day 1 of cycle 2. An interpatient dose escalation
scheme was used, starting from tipifarnib 100mg b.i.d., gemcita-
bine 750mgm
 2 and cisplatin 75mgm
 2. At least three patients
were treated at each dose level. If DLT occurred in a patient during
cycle 1, three additional patients were enrolled in that cohort.
MTD was defined at which 2 or more out of 6 patients (2X6)
experienced DLT. Dose-limiting toxicity was defined as drug-
related nonhaematological toxicity Xgrade 3 (excluding untreated
nausea and vomiting), grade 4 granulocytopenia lasting 45 days,
or associated with fever/infection, grade 4 thrombocytopenia,
interruption of tipifarnib dosing for 44 days because of toxicity
and grade X2 neurotoxicity or ototoxicity, which did not improve
to grade 1 or less within 3 weeks. These toxicities were only
considered DLT if they occurred during the first cycle of treatment.
In the case of grade 3–4 haematological toxicities, the dose of
gemcitabine was adjusted in the next cycle based on nadir blood
cell counts. Dose adjustments were relative to the starting dose of
gemcitabine received in the previous cycle of therapy. If the nadir
granulocyte count was 4500ml
 1 and the nadir platelet count
450000ml
 1, 100% of the planned gemcitabine dose was
administered. If the nadir granulocyte count was p499ml
 1 and/
or the nadir platelet count p49999ml
 1, 75% of the planned
gemcitabine dose was administered. The dose of cisplatin was not
reduced because of haematological toxicities encountered in the
previous cycle. The administration of tipifarnib was discontinued
when haematological DLT occurred. After recovery to at least
grade 1, tipifarnib was reinstituted at the same dose level in
conjunction with a dose modification of gemcitabine. If a patient
continued to experience haematological DLT after one dose
modification of gemcitabine, the dose of tipifarnib was decreased
with 100mg b.i.d. If at any time the dose of tipifarnib was to be
reduced to o100mg b.i.d. or if retreatment needed to be delayed
42 weeks after the scheduled restarting of a cycle, the patient went
off-study. In the case of grade 3–4 nonhaematological toxicities,
the dose of both gemcitabine and cisplatin was adjusted. Dose
adjustments were relative to the starting dose of gemcitabine and
cisplatin received in the previous cycle of therapy. If grade 3
nonhaematological toxicities occurred, patients received 75% of
the planned dose. If grade 4 nonhaematological toxicities occurred,
patients went off-study. No dose adjustments were made for
transaminase elevation unless associated with clinical signs or
symptoms. If a grade 3 nonhaematological DLT occurred (or grade
2 neurotoxicity or ototoxicity), treatment with tipifarnib was
interrupted until the toxicity resolved to grade 1 and was
reinstituted at the discretion of the investigator; a dose modifica-
tion of gemcitabine/cisplatin as well as a dose reduction of
tipifarnib by 100mg b.i.d. was applied. If at any time the dose of
tipifarnib was to be reduced to o100mg b.i.d. or if retreatment
needed to be delayed 42 weeks after the scheduled restarting of a
cycle, the patient went off-study.
Patients with progressive disease were excluded from further
treatment, and patients who were excluded within the first 21 days
for reasons other than drug-related toxicity were replaced.
Patient evaluation and follow-up
Complete patient history, physical examination, haematology,
chemistry, urinalysis and electrocardiogram were performed at
baseline and before each cycle of treatment. Physical examination,
haematology and chemistry were also evaluated on days 8 and
15 of each cycle. Audiometry was performed at baseline and was
repeated if clinically indicated. Indicator lesions were measured
before start of treatment and every two cycles, as a basis for the
assessment of activity of the treatment. All toxicities observed were
graded according to the Common Toxicity Criteria (NCI-CTC,
Version 2.0, 1998).
Pharmacokinetics
Pharmacokinetic studies were performed for each agent during
day 1 of the first cycle and for cisplatin and gemcitabine also
during day 1 of the second cycle. In the second cycle, tipifarnib
was not administered on day 1, to allow for a comparison of
gemcitabine and cisplatin pharmacokinetics with and without
tipifarnib coadministration. In cycle 2, tipifarnib pharmacokinetics
was then determined on day 2. For gemcitabine, 2ml blood
samples were taken at 0, 15, 30, 35, 45, 60, 90min and at 2, 2.5, 24,
32 and 48h after the start of the 30min infusion during cycle 1 and
at 0, 15, 30, 35, 45, 60, 90min during cycle 2. Both gemcitabine
and its metabolite 20,2 0 -difluoro-20-deoxy-uridine (dFdU) were
measured in plasma. Of each blood sample, 1ml was added to
10ml of tetrahydrouridine (10mgml
 1), after which it was
centrifuged for 5min at 41C and 1500g. Subsequently, the plasma
layer was stored at  201C until analysis. Additionally, 15ml blood
samples were taken at 0, 1.5, 4 and 24h after the start of the
gemcitabine infusion for the determination of the triphosphate
metabolite of gemcitabine (dFdCTP) in WBC (Sparidans et al,
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s2002). Isolation of WBC was performed using a Ficoll density
gradient (Pharmacia, Sweden) as described previously (Heinemann
et al, 1998). All gemcitabine levels were measured using a validated
high-performance liquid chromatography (HPLC) method, analo-
gous to the method of Freeman et al (1995). For cisplatin, 5ml
blood samples were obtained at 0, 1.5, 3, 3.25, 3.5, 4, 5, 6.5, 10.5 and
23h after the start of the 3h infusion. Blood samples were
immediately centrifuged for 5min at 41C and 1500g. Unbound
platinum was obtained by ultrafiltration using the MPS-1 system
equipped with 3kDa YMT membranes (Amicon Division, Danvers,
MA, USA). The resulting plasma ultrafiltrate and total plasma were
immediately stored at  201C until analysis by atomic absorption
spectrometry (AAS) (Van Warmerdam et al, 1995). At 0, 4 and 23h
after start of the cisplatin infusion, 15ml blood was collected from
which WBC were isolated for the measurement of platinum-DNA
adducts by a sensitive and validated
32P-postlabelling assay,
enabling the selective determination of Pt-GG and Pt-AG adducts
(Pluim et al, 1999). For tipifarnib, 5ml blood samples were drawn
at 0, 1, 2, 3, 5, 8 and 12h after the morning dose. Immediately after
collection, the blood samples were centrifuged for 5min at 41Ca t
1500g. Separated plasma was stored at  201C for subsequent drug
analysis by a validated HPLC method with UV detection (Zujewski
et al, 2000).
Pharmacokinetic analysis
The following pharmacokinetic parameters were determined using
noncompartmental analysis with WinNonLin software (version
4.1, Pharsight Corporation, Mountain View, CA, USA): the
maximum plasma concentration (Cmax), time to maximum plasma
concentration (tmax), the elimination half-life (t1/2), the area under
the plasma concentration–time curve from 0 to 48h (AUC0–48)o f
gemcitabine and dFdU and the AUC0–23 for total and unbound
(free) platinum. Platinum concentrations obtained by AAS were
back-calculated to the corresponding cisplatin concentrations by
multiplication with the molecular weight. In addition, the AUC0–24
of dFdCTP and the AUA0–23 (area under the adduct curve)
(Schellens et al, 1996) of Pt-DNA adducts were calculated in WBC.
For tipifarnib, Cmax, tmax and AUC0-12 were determined.
Statistical analysis
The primary pharmacokinetic parameters of interest for the
statistical analyses were Cmax and AUC. Only data from patients
who completed the pharmacokinetic blood sampling during the
first and second cycles and had no dose reduction were included in
the analyses. The Cmax and AUC values of the different drugs were
compared between cycle 1 (gemcitabine/cisplatin in the presence
of tipifarnib) and cycle 2 (gemcitabine/cisplatin in the absence
of tipifarnib) using an ANOVA test (Patnaik et al, 2003). A
significance level of 0.05 was used for all analyses. The statistical
analyses were performed using the SAS statistical software
program (version 6.12; SAS Institute, Inc., Cary, NC, USA).
RESULTS
Patient characteristics
A total of 31 patients were included at five different dose levels
(Table 1): 14 male and 17 female, with a median age of 58 years
(range 26–69). Most patients (26 out of 31) had a good
performance status of 0–1 (Table 2). A total of 18 patients had
prior systemic chemotherapy and two of these patients received
previous cisplatin. On the first dose level, one patient was
withdrawn from the study before completing the first cycle, due
to clinical deterioration, and was replaced. Another patient had
received an incorrect dosage and was retrospectively not evaluable
for DLT. At the next level, one of the first three patients
experienced DLT, and three more patients were entered. In this
second cohort, one patient developed severe toxicity (as described
under nonhaematological toxicity, transient grade 3 elevation
ALAT) during cycle 2 and therefore this was not considered as
DLT. For safety reasons, another three patients were included at
this level. This was in agreement with the Institutional Review
Board (IRB). Two patients included at dose level 2 were replaced
because they did not complete the first cycle due to non-drug-
related complications. After the evaluation of all patients included
at level 2, normal dose escalation was resumed. This decision was
supported by results of a concurrent trial of tipifarnib in
Table 1 Doses of gemcitabine, cisplatin and tipifarnib and number of
patients included per dose level
Dose level
Gemcitabine
(mgm
 2)
days 1 and 8
Cisplatin
(mgm
 2)
day 1
Tipifarnib (mg
twice daily) days
1–7 n
1 750 75 100 4
2 750 75 200 11
3 1000 75 200 6
4 1000 100 200 7
5 1000 100 300 3
Table 2 Patient characteristics
n
Gender
Male 14
Female 17
Age
Median (years) 58
Range (years) 26–69
Race
White 30
Black 1
No. of cycles of tipifarnib+gemcitabine and cisplatin
1–2 13
3–4 5
5–6 8
7–8 3
482
Tumour types
Pancreatic 9
ACUP (adenocarcinoma of unknown primary) 6
Ovary 4
Colorectal 3
Gastric 2
Anal canal 2
Bile duct carcinoma 1
Head and neck 1
Mesothelioma 1
Sarcoma 1
Oesophagus 1
Performance status
01 0
11 6
25
Previous therapy
Surgery 19
Radiotherapy 8
Chemotherapy 18
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scombination with gemcitabine and cisplatin in a different
schedule, which had reached higher dose levels already (Adjei
et al, 2003b). At dose level 3, three patients were included initially
and no DLTs were observed. This was also the situation for the
first three patients that were included at dose level 4. At dose level
5, two of the three patients included experienced DLT, and the
dose was lowered to the previous level. At dose level 4, three
additional patients were treated. One of these patients did not
complete cycle 1 and was replaced. Two patients experienced DLT.
For safety reasons, it was decided that dose level 3 was the MTD.
At this level, gemcitabine was given at 1000mgm
 2, cisplatin at
75mgm
 2 and tipifarnib at 200mg b.i.d.. Three extra patients were
included at the MTD level and one DLT was observed.
Haematological toxicity
All patients were evaluable for toxicity and 27 patients (87%)
experienced grade 3–4 adverse events. A summary of the
treatment emergent grade 3–4 haematological and nonhaemato-
logical toxicities are shown in Table 3a and the observed DLTs
are depicted in Table 3b. The main haematological grade 3 or 4
toxicities were neutropenia (32%, one patient had febrile
neutropenia (3%)) and thrombocytopenia (16%). One patient
treated at dose level 1 had a grade 3 neutropenia. At dose level 2,
several cases of grade 3–4 haematological toxicities were observed,
but only thrombocytopenia occurred in cycle 1 and was considered
to be a DLT. At dose level 3 (MTD), patients also experienced
grade 3–4 haematological toxicities. One patient developed dose-
limiting grade 4 thrombocytopenia during cycle 1. At dose level 4,
several severe haematological events were observed. Two patients
developed a DLT that consisted of neutropenia grade 4 in one
patient and febrile neutropenia grade 4, thrombocytopenia grade 4
and electrolyte imbalance grade 3 in the other patient. At dose level
5, patients developed grade 3–4 haematological toxicities but not
during cycle 1. Therefore, these events were not considered to
be a DLT. Owing to haematological toxicities, three patients (10%)
had a dose reduction of tipifarnib and five patients (16%) of
gemcitabine.
Nonhaematological toxicity
The main nonhaematological grade 3 or 4 toxicities were nausea
(26%), vomiting (23%) and fatigue (19%). Nausea and vomiting
frequently occurred in the first week of each cycle, when tipifarnib
Table 3a Incidence of treatment emergent Grade 3 or 4 haematological and nonhaematological toxicities for all cycles observed
Level 1 Level 2 Level 3 Level 4 Level 5 Total
Cohort 1 2 3 4 5
nnnnn n (%)
Total no. of subjects 4 11 6 7 3 31
No. of subjects with Grade 3–4 toxicity 2 11 4 7 3 27 (87)
Haematological
Neutropenia
a 1 3 2 4 1 11 (35)
Anaemia — 3 — 1 — 4 (13)
Thrombocytopenia — 1 2 1 1 5 (16)
Nonhaematological
Nausea — 3 2 2 1 8 (26)
Vomiting — 3 2 2 — 7 (23)
Constipation — — — 2 — 2 (6)
Fatigue — 2 1 1 2 6 (19)
Hypokalemia — — — 3 — 3 (10)
Thrombophlebitis — 2 — — — 2 (6)
Pulmonary embolism 1 ———— 1 ( 3 )
ALAT elevation — 1 — — — 1 (3)
aOne patient treated at dose level 4 developed febrile neutropenia.
Table 3b Dose-limiting toxicities in cycle 1
Level 1 Level 2 Level 3 Level 4 Level 5 Total
Cohort 1 2 3 4 5 n
No. of subjects evaluable for DLT 2/4 9/11 6/6 6/7 3/3 26/31
Subjects with DLT — 1 1 2 2 6
Haematological
Neutropenia — — — 1 — 1
Febrile neutropenia — — — 1 — 1
Thrombocytopenia — 1 1 1 — 3
Nonhaematological
Bilirubinemia — — — 1 — 1
Fatigue — — — — 1 1
Ototoxicity — — — — 1 1
Hypokalemia — — — 1 — 1
Hyponatremia — — — 1 — 1
Tipifarnib in combination with gemcitabine and cisplatin
WS Siegel-Lakhai et al
1225
British Journal of Cancer (2005) 93(11), 1222–1229 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
swas given. In several patients, the intake of tipifarnib was reported
as difficult due to this nausea, which appeared worse than that
observed in single agent trials (Zujewski et al, 2000; Karp et al,
2001; Crul et al, 2002). At dose-level 1, one patient developed a
grade 3–4 pulmonary embolism during cycle 2. At dose levels 2
and 3, several grade 3–4 nonhaematological toxicities were
observed, but these events were not considered to be dose limiting
as the toxicities developed during subsequent cycles. One patient
treated at dose level 2 had a grade 3 elevation of ALAT, but this
was transient. This toxicity was not clearly related to the study
medication and it was decided to rechallenge the patient at the
same doses of the three drugs. This rechallenge proceeded
uneventful. At dose level 4, patients experienced also grade 3–4
nonhaematological toxicities. One patient treated at this dose level
had a DLT that consisted of neutropenia, thrombocytopenia and
electrolyte imbalance. The electrolyte imbalance included grade 3
hypokalemia, hyponatremia and bilirubinemia. It could not be
concluded that the electrolyte imbalance was solely induced by the
combination administered in this study because this patient
received prior cisplatin treatment. The electrolyte imbalance could
be induced by previous tubular damage. At dose level 5, patients
also developed grade 3–4 nonhaematological toxicities. Two
patients experienced DLT consisting of grade 3 fatigue and grade
2 decreased hearing, respectively. Owing to nonhaematological
toxicities, one patient (3%) had a dose reduction of tipifarnib and
four patients (13%) of gemcitabine and cisplatin.
Audiometric evaluations
Three patients had a normal value for audiometric examination at
baseline, but an abnormal evaluation at a later examination. The
first patient was treated at dose level 2 (75mgm
 2 cisplatin) and
had a grade 2 tinnitus in cycle 6. The other patient was treated
at dose level 4 (100mgm
 2 cisplatin) and developed a grade 2
tinnitus in cycle 2. For the patient treated at dose level 5 with the
grade 2 decreased hearing observed in cycle 1 that was considered
to be a DLT, audiometry was not evaluated further.
Pharmacokinetics
Plasma samples for pharmacokinetic studies were obtained from
30 patients for cisplatin, from 23 patients for Pt-adduct analyses in
WBC, from 29 patients for gemcitabine, from 26 patients for
gemcitabine in WBC and from 23 patients for tipifarnib. Not all
pharmacokinetic parameters could be determined for each patient
during cycles 1 and 2 because of an incomplete pharmacokinetic
profile or because of a dose reduction. The plasma pharmacoki-
netic parameters of total and unbound cisplatin following an i.v.
infusion of 75 or 100mgm
 2 cisplatin with or without tipifarnib
are shown in Table 4a. The parameter values of 100mgm
 2 were
adjusted to 75mgm
 2 cisplatin. There were no significant
differences in Cmax and AUC0–23 of total (P¼0.124 and
P¼0.575, respectively) and unbound (P¼0.898 and 0.272,
respectively) cisplatin between cycles 1 and 2.
The AUA0–23 values of Pt-AG and Pt-GG were also adjusted to
the 75mgm
 2 cisplatin dose. For Pt-AG, the AUA0–23values were
in the ranges of 0.76–10.6fmolhmg
 1 DNA and 0.63–
13.1fmolhmg
 1 DNA with and without tipifarnib, respectively.
For Pt-GG, the AUA0–23 values were in the ranges of 7.38–
34.1fmolhmg
 1 DNA and 5.70–34.1fmolhmg
 1 DNA with and
without tipifarnib, respectively. The AUAs of Pt-AG and Pt-GG
were not significantly (P¼0.769 and P¼0.715, respectively)
affected by the administration of tipifarnib.
The pharmacokinetic parameters of gemcitabine, dFdU and
dFdCTP following an i.v. infusion of 750 or 1000mgm
 2
gemcitabine with or without tipifarnib are shown in Table 4b.
The parameter values of 1000mgm
 2 were adjusted to 750mgm
 2
gemcitabine. There were no significant differences in Cmax and
AUC0–48 of gemcitabine (P¼0.197 and P¼0.200, respectively)
and in AUC0–24 of dFdCTP (P¼0.303) between cycles 1 and 2.
However, for dFdU, a significant difference was found in Cmax and
AUC0–48 (P¼0.028 and P¼0.032, respectively) between cycles 1
and 2.
The plasma pharmacokinetic parameters of tipifarnib following
a single 200mg dose of tipifarnib as monotherapy or with
gemcitabine/cisplatin are shown in Table 4c. There were no
statistically significant differences in Cmax and AUC0–12(P¼0.094
and P¼0.918, respectively) between mono- or combination
therapy.
Response
The best response after initiation of therapy is shown in Table 5. Of
the 31 patients, 27 patients had at least one postbaseline response
evaluation. Eight patients achieved a confirmed partial response.
Of these eight patients, two had pancreatic cancer, two had ovarian
cancer, two had anal carcinomas, one had oesophagus cancer and
one patient had ACUP (adenocarcinoma of unknown primary).
Table 4a Mean (s.d.) pharmacokinetic parameters of total and unbound cisplatin, with or without tipifarnib (100–300mg)
Variable Units Gem/cis (s.d.) n¼24 gem/cis+tipifarnib (s.d.) n¼30 P-value
a
Total cisplatin
Median tmax Hours 3.19 3.28 –
Cmax
b mgml
 1 4.72 (1.68) 4.29 (0.78) 0.124
c
AUC0-23
b hmgml
 1 63.0 (8.93) 61.6 (9.78)
d 0.575
c
t1/2 Hours 40.6 (13.2)
e 46.1 (18.4)
c —
Unbound cisplatin
Median tmax Hours 3.03 3.02 —
Cmax
b mgml
 1 1.91 (1.77) 1.59 (0.24) 0.898
c
AUC0-23
b hmgml
 1 6.84 (3.06) 5.80 (1.93)
f 0.272
g
t1/2 Hours 9.01 (8.78)
h 6.65 (18.2)
i —
Pt-AG
AUA0-23
b fmolhmg
 1 2.78
j 2.66
g 0.769
k
Pt-GG
AUA0-23
b fmolhmg
 1 16.70
g 18.52
g 0.715
k
aTwo-sided P-value for testing a difference between the two treatments. Only data from patients who completed the study were included.
bParameter values adjusted to
75mgm
 2 dose of cisplatin.
cn¼24.
dn¼29.
en¼17.
fn¼28.
gn¼23.
hn¼12.
in¼16.
jn¼22.
kn¼15. Gem¼gemcitabine; cis¼cisplatin.
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sThe duration of the partial response was at least 8 weeks in five
patients. Two patients discontinued treatment after five cycles due
to adverse events in one patient and no further clinical benefit in
the other patient. Another patient with partial response discon-
tinued after 10 cycles because of no further clinical benefit and two
other patients discontinued after six cycles due to the physician
decision. In addition to the eight objective responders, 12 patients
remained stable for more than 8 weeks. Of these 12 patients, one
patient had stable disease for more than 6 months prior to disease
progression. Six patients had disease progression and one patient
was not evaluable for tumour response.
DISCUSSION
The FTIs represent a novel class of small molecule inhibitors of cell
signalling. Recently, studies have been reported of single agent
tipifarnib with negative results (Macdonald et al, 2002; Adjei et al,
2003a; Rao et al, 2004). In this study, tipifarnib in combination
with chemotherapy was investigated. The rationale for evaluating
the combination of tipifarnib with gemcitabine and cisplatin was
the preclinical synergistic cytotoxicity observed between gemcita-
bine and tipifarnib (Janssen Research Foundation, 2003) and the
good clinical combination profile of cisplatin and gemcitabine
(Abratt et al, 1997; Crino et al, 1997; Hitt et al, 1998; Burnett et al,
2000; Kaufman et al, 2000; van der Maase et al, 2000). The primary
objective of this study was to determine the safety and MTD of
twice daily oral dosing of tipifarnib for 7 consecutive days, in
combination with i.v. gemcitabine (days 1 and 8) and cisplatin
(day 1) of each 21-day cycle. The schedule of gemcitabine followed
by cisplatin used in this study was selected because this is the
standard schedule used most frequently in the clinic for advanced
NSCLC (Soto-Parra et al, 2000). Tipifarnib was administered for 7
consecutive days and as monotherapy this regimen was safe up to
at least 300mg b.i.d. in cancer patients (Zujewski et al, 2000).
However, in view of the overlapping toxicity (myelosuppression)
of the drugs, a conservative starting dose of 100mg b.i.d. was
chosen for this trial, thus allowing a substantial safety margin.
Previously, a phase I trial of continuous tipifarnib in combination
with gemcitabine, given at 1000mgm
 2 on days 1, 8 and 15 every 4
weeks, has been performed. In this study, the recommended dose
was 200mg b.i.d. and there was no pharmacokinetic interaction
observed (Patnaik et al, 2003). In addition, a phase I trial with
tipifarnib given for 14 days in combination with gemcitabine on
days 1 and 8 and cisplatin on day 1 was also evaluated (Adjei et al,
2003b). In this schedule, 300mg b.i.d. tipifarnib in combination
with 1000mgm
 2 gemcitabine and 75mgm
 2 cisplatin was
defined as the MTD. However, it was noted that with repeated
administration, the doses of gemcitabine and cisplatin had to be
reduced in nine out of 10 patients treated at the MTD because of
nausea, vomiting and fatigue. In our trial, the recommended dose
Table 4b Mean (s.d.) pharmacokinetic parameters of gemcitabine, dFdU and dFdCTP with or without tipifarnib (100–300mg)
Variable Units Gem/cis (s.d.) n¼23 Gem/cis+tipifarnib (s.d.) n¼29 P-value
a
Plasma gemcitabine
Median tmax Hours 0.50 0.50 —
Cmax
b mgml
 1 12.5 (3.53) 12.6 (2.31) 0.197
c
AUC0–48
b hmgml
 1 6.71 (2.12)
d 6.67 (1.07)
e 0.200
f
t1/2 Hours 0.18 (0.06)
d 0.55 (1.77)
g —
Plasma dFdU
Median tmax Hours 0.6
g 0.61
h —
Cmax
b mgml
 1 25.6 (5.47)
g 27.0 (4.89)
h 0.028
g
AUC0–48
b hmgml
 1 237 (89.4)
d 274 (119)
e 0.032
f
t1/2 Hours 32.4 (26.2)
g 10.2 (6.37)
h —
Mononuclear blood cell dFdCTP
AUC0–24
b hnanomolmg protein
 1 18.3 (40.9)
i 14.7 (22.9)
j 0.303
d
aTwo-sided P-value for testing a difference between the two treatments. Only data from patients who completed the study were included.
bParameter values adjusted to
750mgm
 2 dose of gemcitabine.
cn¼22.
dn¼19.
en¼20.
fn¼14.
gn¼24.
hn¼30.
in¼21.
jn¼26. Gem¼gemcitabine; cis¼cisplatin.
Table 4c Mean (s.d.) pharmacokinetic parameters of tipifarnib (200mg) as monotherapy, or with gemcitabine (750–1000mgm
 2) and cisplatin (75–
100mgm
 2)
Variable Units Tipifarnib (s.d.) n¼20 Tipifarnib+gem/cis (s.d.) n¼23 P-value
a
Tipifarnib
Median tmax Hours 3.0 2.1 —
Cmax ngml
 1 499 (275) 635 (366) 0.094
b
AUC0-12 hngml
 1 2630 (1134) 2971 (2089)
c 0.918
b
aTwo-sided P-value in log-scale for testing a difference between the two treatments. Only data from patients who completed the study were included.
bn¼20.
cn¼22.
Gem¼gemcitabine; cis¼cisplatin.
Table 5 Best response during treatment
Overall response
a No. of patients % of patients (N¼27)
Partial response (PR) 8 30
Stable disease (SD) 12 44
Progressive disease (PD) 6 22
Not evaluable (NE) 1 4
aPR; at least 30% decrease in the sum of the longest diameter of target lesions taking
as reference the baseline sum longest diameter. SD; neither sufficient shrinkage to
qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest
sum longest diameter since the treatment started. PD; at least a 20% increase in the
sum of the longest diameter of target lesions taking as references the smallest sum
longest diameter recorded since the treatment started or the appearance of new
lesions.
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sis tipifarnib 200mg b.i.d. for 7 days, in combination with the
standard doses of gemcitabine and cisplatin. Clearly, the dose of
300mg b.i.d. of tipifarnib is too high in combination with the
standard doses of cisplatin and gemcitabine on a day 1–7
schedule, as determined in our trial, or on a day 1–14 schedule,
as established by others (Patnaik et al, 2003). The main DLT was
myelosuppression. Dose-limiting nonhaematological toxicities
included electrolyte imbalance, fatigue and ototoxicity. The latter
was most likely attributable to the fairly high dose of cisplatin
(100mgm
 2), which was administered at the two highest dose
levels. In this study, audiometry was only performed at baseline
and if clinically indicated, it is likely that the level of ototoxicity
was under-reported. As one patient developed a DLT consisting of
grade 2 decreased hearing, it is recommended to formally assess
ototoxicity in future studies using this combination. The electro-
lyte imbalance could be due to previous tubular damage because
the patient received prior cisplatin treatment.
No drug–drug interaction between tipifarnib and total and
unbound cisplatin was observed in this clinical study. This was as
expected because cisplatin is mainly eliminated by the kidneys and
has no known enzyme catalysed metabolism.
No clear difference in the DNA-adduct levels in the presence or
absence of tipifarnib was found. This was also as expected because
the concentrations of cisplatin with or without tipifarnib showed
not much difference.
There was no drug–drug interaction between tipifarnib and
gemcitabine and dFdCTP. This is consistent with the data from the
previous trial (Patnaik et al, 2003). However, in our study, a
significant difference was found between tipifarnib and dFdU.
Gemcitabine is metabolised to its active metabolite dFdCTP by
deoxycytidine kinase and can be deactivated to dFdU by
deoxycytidine deaminase, whereas tipifarnib undergoes glucuro-
nidation and oxidation by the cytochrome P-450 enzymes.
Tipifarnib is predominantly bound to plasma proteins (99%)
(Janssen Research Foundation, 2003), whereas the binding of
gemcitabine to plasma proteins is negligible (Shipley et al, 1992).
Therefore, it is unlikely that inhibition of the metabolism of either
drug, or their displacement from plasma proteins are potential
mechanisms for pharmacokinetic interactions. In vitro studies are
warranted to unravel the mechanism of interaction between
tipifarnib and dFdU. It is expected that the magnitude of the
found interaction has limited or no clinical implications.
The pharmacokinetic parameters of tipifarnib were not sig-
nificantly affected by the concomitant administration of gemcita-
bine and cisplatin. There was substantial interpatient variability in
the pharmacokinetic data of tipifarnib, which has been observed in
single agent phase I trials as well (Zujewski et al, 2000; Karp et al,
2001; Crul et al, 2002).
The present trial demonstrated that tipifarnib in combination
with gemcitabine and cisplatin is safe and that major and clinically
relevant drug–drug interactions were not evident. Consistent with
this finding, the current regimen revealed signs of activity in a
wide variety of tumours. There were eight confirmed partial
responses and 12 patients remained stable for more than 8 weeks.
As this study represents a combination of tipifarnib with an
effective cytotoxic regimen, the promising efficacy results docu-
mented in this study also have to be interpreted with caution.
Nonetheless, phase II studies of this combination in a number of
solid tumours are warranted. It is of interest to determine if this
combination has equal or greater effect than the standard
treatment of gemcitabine and cisplatin alone and more informa-
tion is needed about the mechanism of action of tipifarnib to select
potential surrogate markers to determine if the recommended dose
is also the effective dose.
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